Strongbridge Biopharma completes enrollment in Phase 3 Cushing’s syndrome trial

Strongbridge Biopharma

Strongbridge Biopharma (NASDAQ:SBBP) completed enrollment in its Phase 3 trial of RECORLEV for the treatment of endogenous Cushing’s syndrome, an endocrine disease caused by chronic elevated cortisol exposure. 

A previous Phase 3 study of RECORLEV, a cortisol synthesis inhibitor, met its primary and secondary endpoints, demonstrating a statistically significant normalization rate of urinary free cortisol at six months. The current study enrolled 44 patients to supplement the long-term efficacy and safety information provided by the previous trial.

“If approved, we believe that RECORLEV could become a preferred medical therapy for the treatment of Cushing’s syndrome, a rare and potentially lethal endocrine disease,” Dr. Fredric Cohen, Strongbridge’s CMO, said in a statement.

“We look forward to reporting top-line results from [this] study during the third quarter of 2020 and to submitting [an NDA] for RECORLEV to the FDA approximately six months after these results are available,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.